Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

Marius Wunderle; Jutta Pretscher; Sara Y. Brucker; Bernhard Volz; Arndt Hartmann; Cornelia Fiessler; Alexander Hein; Lothar Häberle; Sebastian M. Jud; Michael P. Lux; Wolfgang Janni; Christian R. Loehberg; Andreas D. Hartkopf; Christina B. Walter; Gerold Baake; Alexander Fridman; Wolfram Malter; Rachel Wuerstlein; Nadia Harbeck; Oliver Hoffmann; Sherko Kümmel; Bernhard Martin; Christoph Thomssen; Heiko Graf; Christopher Wolf; Christian M. Bayer; Carolin C. Hack; Katrin Almstedt; Paul Gass; Felix Heindl; Tobias F. Brodkorb; Naiba Nabieva; Christoph Lindner; Hans Christian Kolberg; Petra Krabisch; Michael Weigel; Dieter Steinfeld-Birg; Andreas Kohls; Cosima Brucker; Volker Schulz; Gunnar Fischer; Volker Pelzer; Diethelm Wallwiener; Brigitte Rack; Tanja Fehm; Achim Rody; Nicolai Maass; Matthias W. Beckmann; Peter A. Fasching; Claudia Rauh

doi:10.1007/s10549-018-05115-6

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

Marius Wunderle, Jutta Pretscher, Sara Y. Brucker, Bernhard Volz, Arndt Hartmann, Cornelia Fiessler, Alexander Hein, Lothar Häberle, Sebastian M. Jud, Michael P. Lux, Wolfgang Janni, Christian R. Loehberg, Andreas D. Hartkopf, Christina B. Walter, Gerold Baake, Alexander Fridman, Wolfram Malter, Rachel Wuerstlein, Nadia Harbeck, Oliver HoffmannSherko Kümmel, Bernhard Martin, Christoph Thomssen, Heiko Graf, Christopher Wolf, Christian M. Bayer, Carolin C. Hack, Katrin Almstedt, Paul Gass, Felix Heindl, Tobias F. Brodkorb, Naiba Nabieva, Christoph Lindner, Hans Christian Kolberg, Petra Krabisch, Michael Weigel, Dieter Steinfeld-Birg, Andreas Kohls, Cosima Brucker, Volker Schulz, Gunnar Fischer, Volker Pelzer, Diethelm Wallwiener, Brigitte Rack, Tanja Fehm, Achim Rody, Nicolai Maass, Matthias W. Beckmann, Peter A. Fasching^*, Claudia Rauh

^*Corresponding author for this work

Clinic of Gynecology and Obstetrics

13 Citations (Scopus)

Abstract

Purpose: Evidence shows that genetic and non-genetic risk factors for breast cancer (BC) differ relative to the molecular subtype. This analysis aimed to investigate associations between epidemiological risk factors and immunohistochemical subtypes in a cohort of postmenopausal, hormone receptor-positive BC patients. Methods: The prospective, single-arm, multicenter phase IV PreFace study (Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy) included 3529 postmenopausal patients with hormone receptor-positive early BC. Data on their epidemiological risk factors were obtained from patients’ diaries and their medical histories. Data on estrogen receptor, progesterone receptor, and HER2 receptor status were obtained from pathology reports. Patients with incomplete information were excluded. Data were analyzed using conditional inference regression analysis, analysis of variance, and the chi-squared test. Results: In a cohort of 3392 patients, the strongest association with the molecular subtypes of BC was found for hormone replacement therapy (HRT) before diagnosis of early BC. The analysis showed that patients who took HRT at diagnosis had luminal A-like BC more often (83.7%) than those who had never taken HRT or had stopped taking it (75.5%). Luminal B-like BC and HER2-positive BC were diagnosed more often in women who had never taken HRT or had stopped taking it (13.3% and 11.2%, respectively) than in women who were taking HRT at diagnosis of BC (8.3% and 8.0%, respectively). Conclusions: This analysis shows an association between HRT and the distribution of molecular subtypes of BC. However, no associations between other factors (e.g., age at diagnosis, body mass index, smoking status, age at menopause, number of deliveries, age at first delivery, breastfeeding history, or family history) were noted.

Original language	English
Journal	Breast Cancer Research and Treatment
Volume	174
Issue number	2
Pages (from-to)	453-461
Number of pages	9
ISSN	0167-6806
DOIs	https://doi.org/10.1007/s10549-018-05115-6
Publication status	Published - 15.04.2019

Funding

Conflict of interest A Hartmann received honoraria from BMS, Roche, MSD, Novartis, AstraZeneca, NanoString, and BioNTech and funding from NanoString, BioNTech, and Janssen-Cilag. MPL received honoraria from Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, Celgene, Eisai, Medac, and Thieme for advisory boards, lectures, and travel support. WJ received research grants from Novartis. ADH participated on advisory boards for Novartis. RW participated on advisory boards for Novartis, AstraZeneca, Pfizer, and Lilly. SK participated on advisory boards for Roche/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, Puma Biotechnology, pfm medical, Pfizer, and MSD Oncology and received funding from Roche and Daiichi Sankyo. CT received honoraria from Amgen, AstraZeneca, Celgene, Genomic Health, Lilly, Na- noString, Novartis, Pfizer, Puma, and Roche for lectures and advisory boards. CCH received honoraria from Roche. PG received honoraria from Novartis, Roche, and PharmaMar. NN received honoraria from Janssen-Cilag and Novartis. HCK received honoraria from Carl Zeiss Meditec, TEVA, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, and Genomic Health and is stock owner of Theraclion and Phaon Scientific GmbH. MW participated on advisory boards for Novartis, Roche, Pfizer, and Celgene. BR participated on advisory boards for Novartis and Roche and received funding from AstraZeneca, Chugai, Lilly, Novartis, Janssen-Cilag, and Sanofi Aventis. TF participated on advisory boards for Novartis, Roche, AstraZeneca, Pfizer, and Daiichi Sankyo. MWB’s institution received research grants from Novartis. PAF received honoraria from Novartis, Roche, Pfizer, and Amgen. CR received honoraria from Novartis, Roche, Celgene, and Eisai. All remaining authors have declared no conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)
Centers: University Cancer Center Schleswig-Holstein (UCCSH)

Access to Document

10.1007/s10549-018-05115-6

Cite this

Wunderle, M., Pretscher, J., Brucker, S. Y., Volz, B., Hartmann, A., Fiessler, C., Hein, A., Häberle, L., Jud, S. M., Lux, M. P., Janni, W., Loehberg, C. R., Hartkopf, A. D., Walter, C. B., Baake, G., Fridman, A., Malter, W., Wuerstlein, R., Harbeck, N., ... Rauh, C. (2019). Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 174(2), 453-461. https://doi.org/10.1007/s10549-018-05115-6

@article{b670b706014449a0958bbaccb213bbfb,

title = "Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer",

abstract = "Purpose: Evidence shows that genetic and non-genetic risk factors for breast cancer (BC) differ relative to the molecular subtype. This analysis aimed to investigate associations between epidemiological risk factors and immunohistochemical subtypes in a cohort of postmenopausal, hormone receptor-positive BC patients. Methods: The prospective, single-arm, multicenter phase IV PreFace study (Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy) included 3529 postmenopausal patients with hormone receptor-positive early BC. Data on their epidemiological risk factors were obtained from patients{\textquoteright} diaries and their medical histories. Data on estrogen receptor, progesterone receptor, and HER2 receptor status were obtained from pathology reports. Patients with incomplete information were excluded. Data were analyzed using conditional inference regression analysis, analysis of variance, and the chi-squared test. Results: In a cohort of 3392 patients, the strongest association with the molecular subtypes of BC was found for hormone replacement therapy (HRT) before diagnosis of early BC. The analysis showed that patients who took HRT at diagnosis had luminal A-like BC more often (83.7\%) than those who had never taken HRT or had stopped taking it (75.5\%). Luminal B-like BC and HER2-positive BC were diagnosed more often in women who had never taken HRT or had stopped taking it (13.3\% and 11.2\%, respectively) than in women who were taking HRT at diagnosis of BC (8.3\% and 8.0\%, respectively). Conclusions: This analysis shows an association between HRT and the distribution of molecular subtypes of BC. However, no associations between other factors (e.g., age at diagnosis, body mass index, smoking status, age at menopause, number of deliveries, age at first delivery, breastfeeding history, or family history) were noted.",

author = "Marius Wunderle and Jutta Pretscher and Brucker, \{Sara Y.\} and Bernhard Volz and Arndt Hartmann and Cornelia Fiessler and Alexander Hein and Lothar H{\"a}berle and Jud, \{Sebastian M.\} and Lux, \{Michael P.\} and Wolfgang Janni and Loehberg, \{Christian R.\} and Hartkopf, \{Andreas D.\} and Walter, \{Christina B.\} and Gerold Baake and Alexander Fridman and Wolfram Malter and Rachel Wuerstlein and Nadia Harbeck and Oliver Hoffmann and Sherko K{\"u}mmel and Bernhard Martin and Christoph Thomssen and Heiko Graf and Christopher Wolf and Bayer, \{Christian M.\} and Hack, \{Carolin C.\} and Katrin Almstedt and Paul Gass and Felix Heindl and Brodkorb, \{Tobias F.\} and Naiba Nabieva and Christoph Lindner and Kolberg, \{Hans Christian\} and Petra Krabisch and Michael Weigel and Dieter Steinfeld-Birg and Andreas Kohls and Cosima Brucker and Volker Schulz and Gunnar Fischer and Volker Pelzer and Diethelm Wallwiener and Brigitte Rack and Tanja Fehm and Achim Rody and Nicolai Maass and Beckmann, \{Matthias W.\} and Fasching, \{Peter A.\} and Claudia Rauh",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = apr,

day = "15",

doi = "10.1007/s10549-018-05115-6",

language = "English",

volume = "174",

pages = "453--461",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "2",

}

Wunderle, M, Pretscher, J, Brucker, SY, Volz, B, Hartmann, A, Fiessler, C, Hein, A, Häberle, L, Jud, SM, Lux, MP, Janni, W, Loehberg, CR, Hartkopf, AD, Walter, CB, Baake, G, Fridman, A, Malter, W, Wuerstlein, R, Harbeck, N, Hoffmann, O, Kümmel, S, Martin, B, Thomssen, C, Graf, H, Wolf, C, Bayer, CM, Hack, CC, Almstedt, K, Gass, P, Heindl, F, Brodkorb, TF, Nabieva, N, Lindner, C, Kolberg, HC, Krabisch, P, Weigel, M, Steinfeld-Birg, D, Kohls, A, Brucker, C, Schulz, V, Fischer, G, Pelzer, V, Wallwiener, D, Rack, B, Fehm, T, Rody, A, Maass, N, Beckmann, MW, Fasching, PA & Rauh, C 2019, 'Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer', Breast Cancer Research and Treatment, vol. 174, no. 2, pp. 453-461. https://doi.org/10.1007/s10549-018-05115-6

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. / Wunderle, Marius; Pretscher, Jutta; Brucker, Sara Y. et al.
In: Breast Cancer Research and Treatment, Vol. 174, No. 2, 15.04.2019, p. 453-461.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

AU - Wunderle, Marius

AU - Pretscher, Jutta

AU - Brucker, Sara Y.

AU - Volz, Bernhard

AU - Hartmann, Arndt

AU - Fiessler, Cornelia

AU - Hein, Alexander

AU - Häberle, Lothar

AU - Jud, Sebastian M.

AU - Lux, Michael P.

AU - Janni, Wolfgang

AU - Loehberg, Christian R.

AU - Hartkopf, Andreas D.

AU - Walter, Christina B.

AU - Baake, Gerold

AU - Fridman, Alexander

AU - Malter, Wolfram

AU - Wuerstlein, Rachel

AU - Harbeck, Nadia

AU - Hoffmann, Oliver

AU - Kümmel, Sherko

AU - Martin, Bernhard

AU - Thomssen, Christoph

AU - Graf, Heiko

AU - Wolf, Christopher

AU - Bayer, Christian M.

AU - Hack, Carolin C.

AU - Almstedt, Katrin

AU - Gass, Paul

AU - Heindl, Felix

AU - Brodkorb, Tobias F.

AU - Nabieva, Naiba

AU - Lindner, Christoph

AU - Kolberg, Hans Christian

AU - Krabisch, Petra

AU - Weigel, Michael

AU - Steinfeld-Birg, Dieter

AU - Kohls, Andreas

AU - Brucker, Cosima

AU - Schulz, Volker

AU - Fischer, Gunnar

AU - Pelzer, Volker

AU - Wallwiener, Diethelm

AU - Rack, Brigitte

AU - Fehm, Tanja

AU - Rody, Achim

AU - Maass, Nicolai

AU - Beckmann, Matthias W.

AU - Fasching, Peter A.

AU - Rauh, Claudia

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Purpose: Evidence shows that genetic and non-genetic risk factors for breast cancer (BC) differ relative to the molecular subtype. This analysis aimed to investigate associations between epidemiological risk factors and immunohistochemical subtypes in a cohort of postmenopausal, hormone receptor-positive BC patients. Methods: The prospective, single-arm, multicenter phase IV PreFace study (Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy) included 3529 postmenopausal patients with hormone receptor-positive early BC. Data on their epidemiological risk factors were obtained from patients’ diaries and their medical histories. Data on estrogen receptor, progesterone receptor, and HER2 receptor status were obtained from pathology reports. Patients with incomplete information were excluded. Data were analyzed using conditional inference regression analysis, analysis of variance, and the chi-squared test. Results: In a cohort of 3392 patients, the strongest association with the molecular subtypes of BC was found for hormone replacement therapy (HRT) before diagnosis of early BC. The analysis showed that patients who took HRT at diagnosis had luminal A-like BC more often (83.7%) than those who had never taken HRT or had stopped taking it (75.5%). Luminal B-like BC and HER2-positive BC were diagnosed more often in women who had never taken HRT or had stopped taking it (13.3% and 11.2%, respectively) than in women who were taking HRT at diagnosis of BC (8.3% and 8.0%, respectively). Conclusions: This analysis shows an association between HRT and the distribution of molecular subtypes of BC. However, no associations between other factors (e.g., age at diagnosis, body mass index, smoking status, age at menopause, number of deliveries, age at first delivery, breastfeeding history, or family history) were noted.

AB - Purpose: Evidence shows that genetic and non-genetic risk factors for breast cancer (BC) differ relative to the molecular subtype. This analysis aimed to investigate associations between epidemiological risk factors and immunohistochemical subtypes in a cohort of postmenopausal, hormone receptor-positive BC patients. Methods: The prospective, single-arm, multicenter phase IV PreFace study (Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy) included 3529 postmenopausal patients with hormone receptor-positive early BC. Data on their epidemiological risk factors were obtained from patients’ diaries and their medical histories. Data on estrogen receptor, progesterone receptor, and HER2 receptor status were obtained from pathology reports. Patients with incomplete information were excluded. Data were analyzed using conditional inference regression analysis, analysis of variance, and the chi-squared test. Results: In a cohort of 3392 patients, the strongest association with the molecular subtypes of BC was found for hormone replacement therapy (HRT) before diagnosis of early BC. The analysis showed that patients who took HRT at diagnosis had luminal A-like BC more often (83.7%) than those who had never taken HRT or had stopped taking it (75.5%). Luminal B-like BC and HER2-positive BC were diagnosed more often in women who had never taken HRT or had stopped taking it (13.3% and 11.2%, respectively) than in women who were taking HRT at diagnosis of BC (8.3% and 8.0%, respectively). Conclusions: This analysis shows an association between HRT and the distribution of molecular subtypes of BC. However, no associations between other factors (e.g., age at diagnosis, body mass index, smoking status, age at menopause, number of deliveries, age at first delivery, breastfeeding history, or family history) were noted.

UR - https://www.scopus.com/pages/publications/85059694085

U2 - 10.1007/s10549-018-05115-6

DO - 10.1007/s10549-018-05115-6

M3 - Journal articles

C2 - 30603996

AN - SCOPUS:85059694085

SN - 0167-6806

VL - 174

SP - 453

EP - 461

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

Abstract

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this